Know Cancer

or
forgot password

An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab


N/A
18 Years
N/A
Not Enrolling
Both
Colon Cancer, Rectal Cancer

Thank you

Trial Information

An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab


Inclusion Criteria:



- Patients must be 18 years older

- Patients must be receiving his/her first dose of bevacizumab

- Patients must sign an informed consent

Exclusion Criteria:

- Patients receiving > 10 mg/kg doses of bevacizumab

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria.

Outcome Time Frame:

3-6 months

Safety Issue:

Yes

Principal Investigator

Sachin Shah, Pharm.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Texas Tech University Health Sciences Center School of Pharmacy

Authority:

United States: Federal Government

Study ID:

07-097

NCT ID:

NCT00849394

Start Date:

November 2007

Completion Date:

June 2012

Related Keywords:

  • Colon Cancer
  • Rectal Cancer
  • bevacizumab
  • proteinuria
  • Colonic Neoplasms
  • Rectal Neoplasms
  • Proteinuria

Name

Location
Parkland Health and Hospital System Dallas, Texas  75235-7786
Ut Southwestern Medical Center Dallas, Texas  75390
VA North Texas Health Care System Dallas, Texas  75216